Project description
Optimisation of T cell therapy
Adoptive T cell therapy, which employs the patient's own cells as a weapon, is considered a breakthrough in the treatment of cancer. However, the production of such immunotherapy products lacks harmonisation with clinical studies. The EU-funded T-OP project aims to bridge this gap by bringing together interdisciplinary teams of scientists working in cell therapy, immunology, protein engineering and bioinformatics alongside large and medium-sized enterprises. The scientific work will focus on cytokines and their role in the therapeutic outcome of adoptive cell therapy, aiming to determine the optimal combination. The project's results will lead to the development of safer and improved immunotherapeutics.
Field of science
- /natural sciences/biological sciences/biochemistry/biomolecules/proteins
- /medical and health sciences/basic medicine/immunology
- /medical and health sciences/clinical medicine/cancer
- /medical and health sciences/medical biotechnology/cells technologies
Programme(s)
Call for proposal
H2020-MSCA-ITN-2020
See other projects for this call
Funding Scheme
MSCA-ITN-ETN - European Training NetworksCoordinator
80539 Muenchen
Germany
Participants (11)
2800 Kgs Lyngby
1081 HV Amsterdam
75654 Paris
63225 Langen
3400 Hillerod
4051 Basel
8952 Schlieren
SK9 5DG Wilmslow
91190 Saint Aubin
51429 Bergisch Gladbach
91120 Jerusalem